Xiaofang Zuo

List of Publications by Citations

180 papers	4,195 citations	35 h-index	55 g-index
193 ext. papers	5,309 ext. citations	5.9 avg, IF	5.78 L-index

#	Paper	IF	Citations
180	Anti-HIV Drug Discovery and Development: Current Innovations and Future Trends. *Journal of Medicinal Chemistry*, **2016**, 59, 2849-78	8.3	199
179	HIV-1 NNRTIs: structural diversity, pharmacophore similarity, and implications for drug design. *Medicinal Research Reviews*, **2013**, 33 Suppl 1, E1-72	14.4	147
178	8-Hydroxyquinoline: a privileged structure with a broad-ranging pharmacological potential. *MedChemComm*, **2015**, 6, 61-74	5	132
177	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) membrane (M) protein inhibits type I and III interferon production by targeting RIG-I/MDA-5 signaling. *Signal Transduction and Targeted Therapy*, **2020**, 5, 299	21	123
176	Inhibitors of SARS-CoV-2 Entry: Current and Future Opportunities. *Journal of Medicinal Chemistry*, **2020**, 63, 12256-12274	8.3	111
175	Discovery of bioactive molecules from CuAAC click-chemistry-based combinatorial libraries. *Drug Discovery Today*, **2016**, 21, 118-132	8.8	101
174	Design, Synthesis, and Evaluation of Thiophene[3,2-d]pyrimidine Derivatives as HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Significantly Improved Drug Resistance Profiles. *Journal of Medicinal Chemistry*, **2016**, 59, 7991-8007	8.3	84
173	Design strategies of novel NNRTIs to overcome drug resistance. *Current Medicinal Chemistry*, **2009**, 16, 3903-17	4.3	83
172	The Journey of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) from Lab to Clinic. *Journal of Medicinal Chemistry*, **2019**, 62, 4851-4883	8.3	74
171	Novel 1,2,3-thiadiazole derivatives as HIV-1 NNRTIs with improved potency: Synthesis and preliminary SAR studies. *Bioorganic and Medicinal Chemistry*, **2009**, 17, 5920-7	3.4	71
170	Recent applications of click chemistry in drug discovery. *Expert Opinion on Drug Discovery*, **2019**, 14, 779-789	6.8	70
169	Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 3: optimization of [1,2,4]triazolo[1,5-a]pyrimidine core via structure-based and physicochemical property-driven approaches. *European Journal of Medicinal Chemistry*, **2015**, 92, 754-65	6.8	69
168	Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants. *Journal of Medicinal Chemistry*, **2017**, 60, 4424-4443	8.3	65
167	1,2,3-Thiadiazole thioacetanilides as a novel class of potent HIV-1 non-nucleoside reverse transcriptase inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2008**, 18, 5368-71	2.9	60
166	Designed multiple ligands: an emerging anti-HIV drug discovery paradigm. *Current Pharmaceutical Design*, **2009**, 15, 1893-917	3.3	57
165	Fused heterocyclic compounds bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 1: design, synthesis and biological evaluation of novel 5,7-disubstituted pyrazolo[1,5-a]pyrimidine derivatives. *Bioorganic and Medicinal Chemistry*, **2014**, 22, 2052-9	3.4	55
164	Overview of Recent Strategic Advances in Medicinal Chemistry. *Journal of Medicinal Chemistry*, **2019**, 62, 9375-9414	8.3	53

163	Fsp: A new parameter for drug-likeness. *Drug Discovery Today*, **2020**, 25, 1839-1845	8.8	52
162	1,2,3-Selenadiazole thioacetanilides: synthesis and anti-HIV activity evaluation. *Bioorganic and Medicinal Chemistry*, **2009**, 17, 6374-9	3.4	48
161	Synthesis and biological evaluation of imidazole thioacetanilides as novel non-nucleoside HIV-1 reverse transcriptase inhibitors. *Bioorganic and Medicinal Chemistry*, **2009**, 17, 5775-81	3.4	48
160	Exploiting the Tolerant Region I of the Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Binding Pocket: Discovery of Potent Diarylpyrimidine-Typed HIV-1 NNRTIs against Wild-Type and E138K Mutant Virus with Significantly Improved Water Solubility and Favorable Safety Profiles. *Journal of Medicinal Chemistry*, **2019**, 62, 2083-2098	8.3	47
159	Recent advances in the discovery and development of novel HIV-1 NNRTI platforms: 2006-2008 update. *Current Medicinal Chemistry*, **2009**, 16, 2876-89	4.3	47
158	New techniques and strategies in drug discovery. *Chinese Chemical Letters*, **2020**, 31, 1695-1708	8.1	45
157	Targeting the entrance channel of NNIBP: Discovery of diarylnicotinamide 1,4-disubstituted 1,2,3-triazoles as novel HIV-1 NNRTIs with high potency against wild-type and E138K mutant virus. *European Journal of Medicinal Chemistry*, **2018**, 151, 339-350	6.8	44
156	Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 2: discovery of novel [1,2,4]Triazolo[1,5-a]pyrimidines using a structure-guided core-refining approach. *European Journal of Medicinal Chemistry*, **2014**, 85, 293-303	6.8	44
155	Novel HIV-1 non-nucleoside reverse transcriptase inhibitors: a patent review (2005 - 2010). *Expert Opinion on Therapeutic Patents*, **2011**, 21, 717-96	6.8	44
154	Synthesis and anti-HIV activity evaluation of 2-(4-(naphthalen-2-yl)-1,2,3-thiadiazol-5-ylthio)-N-acetamides as novel non-nucleoside HIV-1 reverse transcriptase inhibitors. *European Journal of Medicinal Chemistry*, **2009**, 44, 4648-53	6.8	43
153	Identification of Dihydrofuro[3,4- d]pyrimidine Derivatives as Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors with Promising Antiviral Activities and Desirable Physicochemical Properties. *Journal of Medicinal Chemistry*, **2019**, 62, 1484-1501	8.3	41
152	Structural basis for potent and broad inhibition of HIV-1 RT by thiophene[3,2-]pyrimidine non-nucleoside inhibitors. *ELife*, **2018**, 7,	8.9	41
151	Inhibitors of Influenza Virus Polymerase Acidic (PA) Endonuclease: Contemporary Developments and Perspectives. *Journal of Medicinal Chemistry*, **2017**, 60, 3533-3551	8.3	40
150	Sulfanyltriazole/tetrazoles: a promising class of HIV-1 NNRTIs. *Mini-Reviews in Medicinal Chemistry*, **2009**, 9, 1014-23	3.2	39
149	Design, synthesis and biological evaluation of tacrine-1,2,3-triazole derivatives as potent cholinesterase inhibitors. *MedChemComm*, **2018**, 9, 149-159	5	39
148	Design, synthesis and structure-activity relationships of 4-phenyl-1H-1,2,3-triazole phenylalanine derivatives as novel HIV-1 capsid inhibitors with promising antiviral activities. *European Journal of Medicinal Chemistry*, **2020**, 190, 112085	6.8	37
147	Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 4: design, synthesis and biological evaluation of novel imidazo[1,2-a]pyrazines. *European Journal of Medicinal Chemistry*, **2015**, 93, 330-7	6.8	37
146	Discovery of phenylalanine derivatives as potent HIV-1 capsid inhibitors from click chemistry-based compound library. *European Journal of Medicinal Chemistry*, **2018**, 158, 478-492	6.8	36

145	Recent progress in the structural modification and pharmacological activities of ligustrazine derivatives. *European Journal of Medicinal Chemistry*, **2018**, 147, 150-162	6.8	35
144	Discovery of 2-pyridone derivatives as potent HIV-1 NNRTIs using molecular hybridization based on crystallographic overlays. *Bioorganic and Medicinal Chemistry*, **2014**, 22, 1863-72	3.4	35
143	Strategies for the Discovery of Target-Specific or Isoform-Selective Modulators. *Journal of Medicinal Chemistry*, **2015**, 58, 7611-33	8.3	34
142	Structure-based bioisosterism design, synthesis and biological evaluation of novel 1,2,4-triazin-6-ylthioacetamides as potent HIV-1 NNRTIs. *Bioorganic and Medicinal Chemistry Letters*, **2012**, 22, 7155-62	2.9	33
141	Medicinal chemistry insights in the discovery of novel LSD1 inhibitors. *Epigenomics*, **2015**, 7, 1379-96	4.4	32
140	Optimization of N-Substituted Oseltamivir Derivatives as Potent Inhibitors of Group-1 and -2 Influenza A Neuraminidases, Including a Drug-Resistant Variant. *Journal of Medicinal Chemistry*, **2018**, 61, 6379-6397	8.3	32
139	Design, synthesis and anti-HIV evaluation of novel diarylnicotinamide derivatives (DANAs) targeting the entrance channel of the NNRTI binding pocket through structure-guided molecular hybridization. *European Journal of Medicinal Chemistry*, **2014**, 87, 52-62	6.8	31
138	Update on Recent Developments in Small Molecular HIV-1 RNase H Inhibitors (2013-2016): Opportunities and Challenges. *Current Medicinal Chemistry*, **2018**, 25, 1682-1702	4.3	30
137	Discovery and characterization of novel imidazopyridine derivative CHEQ-2 as a potent CDC25 inhibitor and promising anticancer drug candidate. *European Journal of Medicinal Chemistry*, **2014**, 82, 293-307	6.8	29
136	Design, synthesis and primary biological evaluation of the novel 2-pyridone derivatives as potent non-nucleoside HBV inhibitors. *European Journal of Medicinal Chemistry*, **2017**, 136, 144-153	6.8	28
135	Recent developments in the medicinal chemistry of single boron atom-containing compounds. *Acta Pharmaceutica Sinica B*, **2021**, 11, 3035-3059	15.5	28
134	Current insights into anti-HIV drug discovery and development: a review of recent patent literature (2014-2017). *Expert Opinion on Therapeutic Patents*, **2018**, 28, 299-316	6.8	27
133	Discovery of novel anti-HIV agents via Cu(I)-catalyzed azide-alkyne cycloaddition (CuAAC) click chemistry-based approach. *Expert Opinion on Drug Discovery*, **2016**, 11, 857-71	6.2	26
132	Design, synthesis and anti-HIV evaluation of novel diarylpyridine derivatives targeting the entrance channel of NNRTI binding pocket. *European Journal of Medicinal Chemistry*, **2016**, 109, 294-304	6.8	26
131	Discovery of non-peptide small molecular CXCR4 antagonists as anti-HIV agents: Recent advances and future opportunities. *European Journal of Medicinal Chemistry*, **2016**, 114, 65-78	6.8	26
130	Exploring the hydrophobic channel of NNIBP leads to the discovery of novel piperidine-substituted thiophene[3,2-]pyrimidine derivatives as potent HIV-1 NNRTIs. *Acta Pharmaceutica Sinica B*, **2020**, 10, 878-894	15.5	26
129	Discovery of Novel Diarylpyrimidine Derivatives as Potent HIV-1 NNRTIs Targeting the "NNRTI Adjacent" Binding Site. *ACS Medicinal Chemistry Letters*, **2018**, 9, 334-338	4.3	25
128	Recent advances in antiviral activity of benzo/heterothiadiazine dioxide derivatives. *Current Medicinal Chemistry*, **2008**, 15, 1529-40	4.3	25

127	First discovery of novel 3-hydroxy-quinazoline-2,4(1H,3H)-diones as specific anti-vaccinia and adenovirus agents via Rprivileged scaffoldRrefining approach. *Bioorganic and Medicinal Chemistry Letters*, **2016**, 26, 5182-5186	2.9	25
126	Influenza A virus polymerase: an attractive target for next-generation anti-influenza therapeutics. *Drug Discovery Today*, **2018**, 23, 503-518	8.8	24
125	Design, synthesis and evaluation of pyrazole derivatives as non-nucleoside hepatitis B virus inhibitors. *European Journal of Medicinal Chemistry*, **2016**, 123, 202-210	6.8	24
124	Discovery of novel diarylpyrimidines as potent HIV NNRTIs via a structure-guided core-refining approach. *European Journal of Medicinal Chemistry*, **2014**, 80, 112-21	6.8	24
123	Arylazolylthioacetanilide. Part 8: Design, synthesis and biological evaluation of novel 2-(2-(2,4-dichlorophenyl)-2H-1,2,4-triazol-3-ylthio)-N-arylacetamides as potent HIV-1 inhibitors. *European Journal of Medicinal Chemistry*, **2011**, 46, 5039-45	6.8	24
122	Functional roles of azoles motif in anti-HIV agents. *Current Medicinal Chemistry*, **2011**, 18, 29-46	4.3	24
121	Discovery of novel 1,4-disubstituted 1,2,3-triazole phenylalanine derivatives as HIV-1 capsid inhibitors. *RSC Advances*, **2019**, 9, 28961-28986	3.7	24
120	Contemporary medicinal-chemistry strategies for the discovery of selective butyrylcholinesterase inhibitors. *Drug Discovery Today*, **2019**, 24, 629-635	8.8	24
119	Structure-Based Optimization of N-Substituted Oseltamivir Derivatives as Potent Anti-Influenza A Virus Agents with Significantly Improved Potency against Oseltamivir-Resistant N1-H274Y Variant. *Journal of Medicinal Chemistry*, **2018**, 61, 9976-9999	8.3	24
118	Discovery of Thiophene[3,2-]pyrimidine Derivatives as Potent HIV-1 NNRTIs Targeting the Tolerant Region I of NNIBP. *ACS Medicinal Chemistry Letters*, **2017**, 8, 1188-1193	4.3	21
117	Discovery of potent HIV-1 non-nucleoside reverse transcriptase inhibitors from arylthioacetanilide structural motif. *European Journal of Medicinal Chemistry*, **2015**, 102, 167-79	6.8	21
116	Further Exploring Solvent-Exposed Tolerant Regions of Allosteric Binding Pocket for Novel HIV-1 NNRTIs Discovery. *ACS Medicinal Chemistry Letters*, **2018**, 9, 370-375	4.3	21
115	Discovery of C-1 modified oseltamivir derivatives as potent influenza neuraminidase inhibitors. *European Journal of Medicinal Chemistry*, **2018**, 146, 220-231	6.8	21
114	5-Hydroxypyrido[2,3-b]pyrazin-6(5H)-one derivatives as novel dual inhibitors of HIV-1 reverse transcriptase-associated ribonuclease H and integrase. *European Journal of Medicinal Chemistry*, **2018**, 155, 714-724	6.8	21
113	Synthesis and anti-HIV activity evaluation of novel N?-arylidene-2-[1-(naphthalen-1-yl)-1H-tetrazol-5-ylthio]acetohydrazides. *Medicinal Chemistry Research*, **2010**, 19, 652-663	2.2	21
112	Discovery and Characterization of Fluorine-Substituted Diarylpyrimidine Derivatives as Novel HIV-1 NNRTIs with Highly Improved Resistance Profiles and Low Activity for the hERG Ion Channel. *Journal of Medicinal Chemistry*, **2020**, 63, 1298-1312	8.3	20
111	Structure-Based Bioisosterism Yields HIV-1 NNRTIs with Improved Drug-Resistance Profiles and Favorable Pharmacokinetic Properties. *Journal of Medicinal Chemistry*, **2020**, 63, 4837-4848	8.3	20
110	Novel urate transporter 1 (URAT1) inhibitors: a review of recent patent literature (2016-2019). *Expert Opinion on Therapeutic Patents*, **2019**, 29, 871-879	6.8	20

109	Design, synthesis and preliminary SAR studies of novel N-arylmethyl substituted piperidine-linked aniline derivatives as potent HIV-1 NNRTIs. *Bioorganic and Medicinal Chemistry*, **2014**, 22, 633-42	3.4	20
108	Discovery of small molecular inhibitors targeting HIV-1 gp120-CD4 interaction drived from BMS-378806. *European Journal of Medicinal Chemistry*, **2014**, 86, 481-90	6.8	20
107	Multivalent Agents: A Novel Concept and Preliminary Practice in Anti-HIV Drug Discovery. *Current Medicinal Chemistry*, **2013**, 20, 815-832	4.3	20
106	1,2,3-thiadiazole thioacetanilides. Part 2: Synthesis and biological evaluation of a new series of 2-{[4-(3,4-dichlorophenyl)-1,2,3-thiadiazol-5-yl]sulfanyl}acetanilides as HIV-1 inhibitors. *Chemistry and Biodiversity*, **2010**, 7, 1717-27	2.5	20
105	Structural optimization of pyridine-type DAPY derivatives to exploit the tolerant regions of the NNRTI binding pocket. *European Journal of Medicinal Chemistry*, **2016**, 121, 352-363	6.8	20
104	Discovery of HCV NS5B thumb site I inhibitors: core-refining from benzimidazole to indole scaffold. *European Journal of Medicinal Chemistry*, **2015**, 94, 218-28	6.8	19
103	Novel diarylpyrimidines and diaryltriazines as potent HIV-1 NNRTIs with dramatically improved solubility: a patent evaluation of US20140378443A1. *Expert Opinion on Therapeutic Patents*, **2016**, 26, 281-9	6.8	19
102	Naturally occurring and synthetic bioactive molecules as novel non-nucleoside HBV inhibitors. *Mini-Reviews in Medicinal Chemistry*, **2010**, 10, 162-71	3.2	19
101	Design, synthesis and biological evaluation of "Multi-Site"-binding influenza virus neuraminidase inhibitors. *European Journal of Medicinal Chemistry*, **2019**, 178, 64-80	6.8	18
100	Recent advances in the structure-based rational design of TNKSIs. *Molecular BioSystems*, **2014**, 10, 2783-99		18
99	Design, Synthesis, and Mechanism Study of Benzenesulfonamide-Containing Phenylalanine Derivatives as Novel HIV-1 Capsid Inhibitors with Improved Antiviral Activities. *Journal of Medicinal Chemistry*, **2020**, 63, 4790-4810	8.3	18
98	Discovery of uracil-bearing DAPYs derivatives as novel HIV-1 NNRTIs via crystallographic overlay-based molecular hybridization. *European Journal of Medicinal Chemistry*, **2017**, 130, 209-222	6.8	17
97	Identification of Chebulinic Acid and Chebulagic Acid as Novel Influenza Viral Neuraminidase Inhibitors. *Frontiers in Microbiology*, **2020**, 11, 182	5.7	17
96	Multivalent agents: a novel concept and preliminary practice in Anti-HIV drug discovery. *Current Medicinal Chemistry*, **2013**, 20, 815-32	4.3	17
95	Novel fused pyrimidine and isoquinoline derivatives as potent HIV-1 NNRTIs: a patent evaluation of WO2016105532A1, WO2016105534A1 and WO2016105564A1. *Expert Opinion on Therapeutic Patents*, **2017**, 27, 383-391	6.8	16
94	Discovery of novel DAPY-IAS hybrid derivatives as potential HIV-1 inhibitors using molecular hybridization based on crystallographic overlays. *Bioorganic and Medicinal Chemistry*, **2017**, 25, 4397-4406	3.4	16
93	Molecular design opportunities presented by solvent-exposed regions of target proteins. *Medicinal Research Reviews*, **2019**, 39, 2194-2238	14.4	16
92	Design, synthesis and evaluation of novel HIV-1 NNRTIs with dual structural conformations targeting the entrance channel of the NNRTI binding pocket. *European Journal of Medicinal Chemistry*, **2016**, 115, 53-62	6.8	16

91	Discovery of piperidine-substituted thiazolo[5,4-d]pyrimidine derivatives as potent and orally bioavailable HIV-1 non-nucleoside reverse transcriptase inhibitors. *Communications Chemistry*, **2019**, 2,	6.3	15
90	Discovery of novel piperidine-substituted indolylarylsulfones as potent HIV NNRTIs via structure-guided scaffold morphing and fragment rearrangement. *European Journal of Medicinal Chemistry*, **2017**, 126, 190-201	6.8	15
89	Discovery of nitropyridine derivatives as potent HIV-1 non-nucleoside reverse transcriptase inhibitors via a structure-based core refining approach. *European Journal of Medicinal Chemistry*, **2014**, 76, 531-8	6.8	15
88	Efficient drug discovery by rational lead hybridization based on crystallographic overlay. *Drug Discovery Today*, **2019**, 24, 805-813	8.8	15
87	Synthesis and Preliminary Antiviral Activities of Piperidine-substituted Purines against HIV and Influenza A/H1N1 Infections. *Chemical Biology and Drug Design*, **2015**, 86, 568-77	2.9	14
86	Non-nucleoside anti-HBV agents: advances in structural optimization and mechanism of action investigations. *MedChemComm*, **2015**, 6, 521-535	5	13
85	Design, Synthesis, and Anti-HIV Evaluation of Novel Triazine Derivatives Targeting the Entrance Channel of the NNRTI Binding Pocket. *Chemical Biology and Drug Design*, **2015**, 86, 122-8	2.9	13
84	Targeting the entry step of SARS-CoV-2: a promising therapeutic approach. *Signal Transduction and Targeted Therapy*, **2020**, 5, 98	21	13
83	Synthesis and Biological Evaluation of a Series of 2-((1-substituted-1H-1,2,3-triazol-4-yl)methylthio)-6-(naphthalen-1-ylmethyl)pyrimidin-4(3H)-one As Potential HIV-1 Inhibitors. *Chemical Biology and Drug Design*, **2015**, 86, 614-8	2.9	13
82	Discovery of novel 2-(3-(2-chlorophenyl)pyrazin-2-ylthio)-N-arylacetamides as potent HIV-1 inhibitors using a structure-based bioisosterism approach. *Bioorganic and Medicinal Chemistry*, **2012**, 20, 6795-802	3.4	13
81	Blocking nuclear import of pre-integration complex: an emerging anti-HIV-1 drug discovery paradigm. *Current Medicinal Chemistry*, **2010**, 17, 495-503	4.3	13
80	1-Hydroxypyrido[2,3-d]pyrimidin-2(1H)-ones as novel selective HIV integrase inhibitors obtained via privileged substructure-based compound libraries. *Bioorganic and Medicinal Chemistry*, **2017**, 25, 5779-5789	3.4	12
79	SARS-CoV-2 NSP5 and N protein counteract the RIG-I signaling pathway by suppressing the formation of stress granules.. *Signal Transduction and Targeted Therapy*, **2022**, 7, 22	21	12
78	Discovery of novel 1,2,3-triazole oseltamivir derivatives as potent influenza neuraminidase inhibitors targeting the 430-cavity. *European Journal of Medicinal Chemistry*, **2020**, 187, 111940	6.8	12
77	Design, synthesis and biological evaluation of novel acetamide-substituted doravirine and its prodrugs as potent HIV-1 NNRTIs. *Bioorganic and Medicinal Chemistry*, **2019**, 27, 447-456	3.4	12
76	Identification of highly potent and selective Cdc25 protein phosphatases inhibitors from miniaturization click-chemistry-based combinatorial libraries. *European Journal of Medicinal Chemistry*, **2019**, 183, 111696	6.8	11
75	In situ click chemistry-based rapid discovery of novel HIV-1 NNRTIs by exploiting the hydrophobic channel and tolerant regions of NNIBP. *European Journal of Medicinal Chemistry*, **2020**, 193, 112237	6.8	11
74	Medicinal chemistry insights into novel CDC25 inhibitors. *European Journal of Medicinal Chemistry*, **2020**, 201, 112374	6.8	11

73	Design, synthesis and anti-HIV evaluation of novel diarylpyridine derivatives as potent HIV-1 NNRTIs. *European Journal of Medicinal Chemistry*, **2017**, 140, 383-391	6.8	11
72	Arylazolyl(azinyl)thioacetanilide. Part 9: Synthesis and biological investigation of thiazolylthioacetamides derivatives as a novel class of potential antiviral agents. *Archives of Pharmacal Research*, **2012**, 35, 975-86	6.1	11
71	2,4,5-Trisubstituted Pyrimidines as Potent HIV-1 NNRTIs: Rational Design, Synthesis, Activity Evaluation, and Crystallographic Studies. *Journal of Medicinal Chemistry*, **2021**, 64, 4239-4256	8.3	11
70	Arylazolyl(azinyl)thioacetanilides. Part 16: Structure-based bioisosterism design, synthesis and biological evaluation of novel pyrimidinylthioacetanilides as potent HIV-1 inhibitors. *Bioorganic and Medicinal Chemistry*, **2014**, 22, 5290-7	3.4	9
69	Designing influenza polymerase acidic endonuclease inhibitors via Rprivileged scaffoldR re-evolution/refining strategy. *Future Medicinal Chemistry*, **2019**,	4.1	8
68	Inhibition of CDC25B With WG-391D Impedes the Tumorigenesis of Ovarian Cancer. *Frontiers in Oncology*, **2019**, 9, 236	5.3	8
67	Structure-Activity Relationship Exploration of NNIBP Tolerant Region I Leads to Potent HIV-1 NNRTIs. *ACS Infectious Diseases*, **2020**, 6, 2225-2234	5.5	8
66	First discovery of a potential carbonate prodrug of NNRTI drug candidate RDEA427 with submicromolar inhibitory activity against HIV-1 K103N/Y181C double mutant strain. *Bioorganic and Medicinal Chemistry Letters*, **2018**, 28, 1348-1351	2.9	8
65	Design, synthesis, and antiviral evaluation of novel hydrazone-substituted thiophene[3,2-d]pyrimidine derivatives as potent human immunodeficiency virus-1 inhibitors. *Chemical Biology and Drug Design*, **2018**, 92, 2009-2021	2.9	8
64	The development of an effective synthetic route of lesinurad (RDEA594). *Chemistry Central Journal*, **2017**, 11, 86		8
63	Cosalane and its analogues: a unique class of anti-HIV agents. *Mini-Reviews in Medicinal Chemistry*, **2010**, 10, 966-76	3.2	8
62	Discovery and optimization of benzenesulfonamides-based hepatitis B virus capsid modulators via contemporary medicinal chemistry strategies. *European Journal of Medicinal Chemistry*, **2020**, 206, 112714	6.8	8
61	Novel Human Urate Transporter 1 Inhibitors as Hypouricemic Drug Candidates with Favorable Druggability. *Journal of Medicinal Chemistry*, **2020**, 63, 10829-10854	8.3	8
60	Design, synthesis, and biologic evaluation of novel galloyl derivatives as HIV-1 RNase H inhibitors. *Chemical Biology and Drug Design*, **2019**, 93, 582-589	2.9	8
59	Discovery of potent HIV-1 non-nucleoside reverse transcriptase inhibitors by exploring the structure-activity relationship of solvent-exposed regions I. *Chemical Biology and Drug Design*, **2019**, 93, 430-437	2.9	8
58	Design, synthesis, and evaluation of novel heteroaryldihydropyrimidine derivatives as non-nucleoside hepatitis B virus inhibitors by exploring the solvent-exposed region. *Chemical Biology and Drug Design*, **2020**, 95, 567-583	2.9	8
57	Resurrecting the Condemned: Identification of N-Benzoxaborole Benzofuran GSK8175 as a Clinical Candidate with Reduced Metabolic Liability. *Journal of Medicinal Chemistry*, **2019**, 62, 3251-3253	8.3	7
56	The discovery of novel diarylpyri(mi)dine derivatives with high level activity against a wide variety of HIV-1 strains as well as against HIV-2. *Bioorganic and Medicinal Chemistry*, **2018**, 26, 2051-2060	3.4	7

55	Arylazolyl(azinyl)thioacetanilides: Part 19: Discovery of Novel Substituted Imidazo[4,5-b]pyridin-2-ylthioacetanilides as Potent HIV NNRTIs Via a Structure-based Bioisosterism Approach. *Chemical Biology and Drug Design*, **2016**, 88, 241-53	2.9	7
54	Discovery of novel indolylarylsulfones as potent HIV-1 NNRTIs via structure-guided scaffold morphing. *European Journal of Medicinal Chemistry*, **2019**, 182, 111619	6.8	7
53	Design, synthesis and biological evaluation of 3-hydroxyquinazoline-2,4(1H,3H)-diones as dual inhibitors of HIV-1 reverse transcriptase-associated RNase H and integrase. *Bioorganic and Medicinal Chemistry*, **2019**, 27, 3836-3845	3.4	7
52	Discovery of novel pyridazinylthioacetamides as potent HIV-1 NNRTIs using a structure-based bioisosterism approach. *MedChemComm*, **2013**, 4, 810	5	7
51	One-minute self-assembly of millimetre-long DAST crystalline microbelts via substrate-supported rapid evaporation crystallization. *RSC Advances*, **2017**, 7, 31691-31695	3.7	7
50	3D-QSAR and docking studies on piperidine-substituted diarylpyrimidine analogues as HIV-1 reverse transcriptase inhibitors. *Medicinal Chemistry Research*, **2015**, 24, 3314-3326	2.2	7
49	Arylazolyl(azinyl)thioacetanilides. Part 20: Discovery of novel purinylthioacetanilides derivatives as potent HIV-1 NNRTIs via a structure-based bioisosterism approach. *Bioorganic and Medicinal Chemistry*, **2016**, 24, 4424-4433	3.4	7
48	Punicalagin is a neuraminidase inhibitor of influenza viruses. *Journal of Medical Virology*, **2021**, 93, 3465-3472	3.7	7
47	Contemporary medicinal-chemistry strategies for discovery of blood coagulation factor Xa inhibitors. *Expert Opinion on Drug Discovery*, **2019**, 14, 915-931	6.2	6
46	Fragment-based approaches to anti-HIV drug discovery: state of the art and future opportunities. *Expert Opinion on Drug Discovery*, **2015**, 10, 1271-81	6.2	6
45	Design, diversity-oriented synthesis and biological evaluation of novel heterocycle derivatives as non-nucleoside HBV capsid protein inhibitors. *European Journal of Medicinal Chemistry*, **2020**, 202, 112495	6.8	6
44	Pyrazolo[1,5-a]pyrimidine-based macrocycles as novel HIV-1 inhibitors: a patent evaluation of WO2015123182. *Expert Opinion on Therapeutic Patents*, **2016**, 26, 979-86	6.8	6
43	Design, synthesis and biological evaluation of novel trimethylpyrazine-2-carbonyloxy-cinnamic acids as potent cardiovascular agents. *MedChemComm*, **2014**, 5, 711	5	6
42	Design, synthesis and biological evaluation of novel ligustrazinylated derivatives as potent cardiovascular agents. *MedChemComm*, **2013**, 4, 827-832	5	6
41	An insight on medicinal aspects of novel HIV-1 capsid protein inhibitors. *European Journal of Medicinal Chemistry*, **2021**, 217, 113380	6.8	6
40	Design, Synthesis, and Biological Evaluation of Novel 2-(Pyridin-3-yloxy)acetamide Derivatives as Potential Anti-HIV-1 Agents. *Chemical Biology and Drug Design*, **2016**, 87, 283-9	2.9	6
39	Novel indolylarylsulfone derivatives as covalent HIV-1 reverse transcriptase inhibitors specifically targeting the drug-resistant mutant Y181C. *Bioorganic and Medicinal Chemistry*, **2021**, 30, 115927	3.4	6
38	Contemporary Medicinal Chemistry Strategies for the Discovery and Development of Novel HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors.. *Journal of Medicinal Chemistry*, **2022**,	8.3	6

37	Discovery of novel anti-influenza agents via contemporary medicinal chemistry strategies (2014-2018 update). *Future Medicinal Chemistry*, **2019**, 11, 375-378	4.1	5
36	Discovery of novel "Dual-site" binding oseltamivir derivatives as potent influenza virus neuraminidase inhibitors. *European Journal of Medicinal Chemistry*, **2020**, 191, 112147	6.8	5
35	Identification of spirocyclic or phosphate substituted quinolizine derivatives as novel HIV-1 integrase inhibitors: a patent evaluation of WO2016094197A1, WO2016094198A1 and WO2016154527A1. *Expert Opinion on Therapeutic Patents*, **2017**, 27, 1277-1286	6.8	5
34	Novel diaryltriazines with a picolinonitrile moiety as potent HIV-1 RT inhibitors: a patent evaluation of WO2016059647(A2). *Expert Opinion on Therapeutic Patents*, **2017**, 27, 9-15	6.8	5
33	Design, synthesis, and biological evaluation of piperidinyl-substituted [1,2,4]triazolo[1,5-a]pyrimidine derivatives as potential anti-HIV-1 agents with reduced cytotoxicity. *Chemical Biology and Drug Design*, **2021**, 97, 67-76	2.9	5
32	Design, synthesis, and evaluation of "dual-site"-binding diarylpyrimidines targeting both NNIBP and the NNRTI adjacent site of the HIV-1 reverse transcriptase. *European Journal of Medicinal Chemistry*, **2021**, 211, 113063	6.8	5
31	Medicinal chemistry strategies towards the development of effective SARS-CoV-2 inhibitors. *Acta Pharmaceutica Sinica B*, **2021**,	15.5	5
30	The development of an effective synthetic route of rilpivirine. *BMC Chemistry*, **2021**, 15, 22	3.7	4
29	Exploiting the tolerant region I of the non-nucleoside reverse transcriptase inhibitor (NNRTI) binding pocket. Part 2: Discovery of diarylpyrimidine derivatives as potent HIV-1 NNRTIs with high Fsp values and favorable drug-like properties. *European Journal of Medicinal Chemistry*, **2021**, 213, 113051	6.8	4
28	Boronic acid-containing diarylpyrimidine derivatives as novel HIV-1 NNRTIs: Design, synthesis and biological evaluation. *Chinese Chemical Letters*, **2021**,	8.1	4
27	Design, synthesis, and mechanism study of dimerized phenylalanine derivatives as novel HIV-1 capsid inhibitors. *European Journal of Medicinal Chemistry*, **2021**, 226, 113848	6.8	4
26	Design, Synthesis, and Biological Evaluation of Novel 4-Aminopiperidinyl-linked 3,5-Disubstituted-1,2,6-thiadiazine-1,1-dione Derivatives as HIV-1 NNRTIs. *Chemical Biology and Drug Design*, **2015**, 86, 107-13	2.9	3
25	Facile Synthesis of Derivatives of 1,1,3-Trioxo-2H,4H-pyrrolo[1,2-b][1,2,4,6]thiatriazine: A New Heterocyclic System. *Heteroatom Chemistry*, **2013**, 24, 495-501	1.2	3
24	Targeting dual tolerant regions of binding pocket: Discovery of novel morpholine-substituted diarylpyrimidines as potent HIV-1 NNRTIs with significantly improved water solubility. *European Journal of Medicinal Chemistry*, **2020**, 206, 112811	6.8	3
23	Discovery of highly potent and selective influenza virus neuraminidase inhibitors targeting 150-cavity. *European Journal of Medicinal Chemistry*, **2021**, 212, 113097	6.8	3
22	Discovery, optimization, and target identification of novel coumarin derivatives as HIV-1 reverse transcriptase-associated ribonuclease H inhibitors. *European Journal of Medicinal Chemistry*, **2021**, 225, 113769	6.8	3
21	Substituted indoles as HIV-1 non-nucleoside reverse transcriptase inhibitors: a patent evaluation (WO2015044928). *Expert Opinion on Therapeutic Patents*, **2016**, 26, 629-35	6.8	2
20	Indolylarylsulfones bearing phenylboronic acid and phenylboronate ester functionalities as potent HIV-1 non-nucleoside reverse transcriptase inhibitors. *Bioorganic and Medicinal Chemistry*, **2021**, 53, 116531	3.4	2

19	Identification of novel potent HIV-1 inhibitors by exploiting the tolerant regions of the NNRTIs binding pocket. *European Journal of Medicinal Chemistry*, **2021**, 214, 113204	6.8	2
18	Design, synthesis and anti-HIV evaluation of novel 5-substituted diarylpyrimidine derivatives as potent HIV-1 NNRTIs. *Bioorganic and Medicinal Chemistry*, **2021**, 40, 116195	3.4	2
17	Design, synthesis, and biological evaluation of novel 5-Alkyl-6-Adamantylmethylpyrimidin-4(3H)-ones as HIV-1 non-nucleoside reverse-transcriptase inhibitors. *Chemical Biology and Drug Design*, **2016**, 88, 380-5	2.9	2
16	Discovery of Novel Dihydrothiopyrano[4,3-]pyrimidine Derivatives as Potent HIV-1 NNRTIs with Significantly Reduced hERG Inhibitory Activity and Improved Resistance Profiles. *Journal of Medicinal Chemistry*, **2021**, 64, 13658-13675	8.3	2
15	Discovery of potent and selective Cdc25 phosphatase inhibitors via rapid assembly and in situ screening of Quinonoid-focused libraries. *Bioorganic Chemistry*, **2021**, 115, 105254	5.1	2
14	Design, synthesis and evaluation of heteroaryldihydropyrimidine analogues bearing spiro ring as hepatitis B virus capsid protein inhibitors. *European Journal of Medicinal Chemistry*, **2021**, 225, 113780	6.8	2
13	Design, synthesis, and mechanistic investigations of phenylalanine derivatives containing a benzothiazole moiety as HIV-1 capsid inhibitors with improved metabolic stability. *European Journal of Medicinal Chemistry*, **2022**, 227, 113903	6.8	1
12	Discovery and optimizing polycyclic pyridone compounds as anti-HBV agents. *Expert Opinion on Therapeutic Patents*, **2020**, 30, 715-721	6.8	1
11	SARS-CoV-2 Entry inhibitors targeting virus-ACE2 or virus-TMPRSS2 interactions. *Current Medicinal Chemistry*, **2021**,	4.3	1
10	Exploiting the hydrophobic channel of the NNIBP: Discovery of novel diarylpyrimidines as HIV-1 NNRTIs against wild-type and K103N mutant viruses. *Bioorganic and Medicinal Chemistry*, **2021**, 42, 116239	3.4	1
9	Search, Identification, and Design of Effective Antiviral Drugs Against Pandemic Human Coronaviruses. *Advances in Experimental Medicine and Biology*, **2021**, 1322, 219-260	3.6	1
8	Development of a practical synthesis of etravirine via a microwave-promoted amination. *Chemistry Central Journal*, **2018**, 12, 144		1
7	Structure-Based Design and Discovery of Pyridyl-Bearing Fused Bicyclic HIV-1 Inhibitors: Synthesis, Biological Characterization, and Molecular Modeling Studies. *Journal of Medicinal Chemistry*, **2021**, 64, 13604-13621	8.3	1
6	Design, synthesis, and antiviral evaluation of novel piperidine-substituted arylpyrimidines as HIV-1 NNRTIs by exploring the hydrophobic channel of NNIBP. *Bioorganic Chemistry*, **2021**, 116, 105353	5.1	1
5	Design, synthesis, and antiviral activity of phenylalanine derivatives as HIV-1 capsid inhibitors. *Bioorganic and Medicinal Chemistry*, **2021**, 48, 116414	3.4	0
4	Novel RNase H inhibitors blocking RNA-directed strand displacement DNA synthesis by HIV-1 reverse transcriptase.. *Journal of Molecular Biology*, **2022**, 167507	6.5	0
3	Discovery of potential dual-target prodrugs of HIV-1 reverse transcriptase and nucleocapsid protein 7. *Bioorganic and Medicinal Chemistry Letters*, **2020**, 30, 127287	2.9	
2	Recent Developments in Small Molecular HIV-1 and Hepatitis B Virus RNase H Inhibitors **2020**, 273-292		

1 Advances in Natural Products-Based Antiviral Agents **2021**, 21-42